NRGN and Alzheimer disease: In patients with mild AD, 24 weeks of treatment with orally administered neflamapimod showed a tendency towards the conservation of episodic memory (but only at high doses), interpreted as an indicator of mildly enhanced plasticity, with a moderate decrease in CSF neurogranin.